All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 27, 2023
Home » Topics » Respiratory, BioWorld Science

Respiratory, BioWorld Science
Respiratory, BioWorld Science RSS Feed RSS

Respiratory

Chiesi Farmaceutici discloses new DDR1/DDR2 inhibitors

Oct. 21, 2022
No Comments
Chiesi Farmaceutici SpA has synthesized new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
Read More
SARS-CoV-2 virus particles
Infection

At IDWeek, new insights into long COVID

Oct. 21, 2022
By Mar de Miguel
No Comments
Three years after WHO declared the COVID-19 pandemic, some patients are still reporting symptoms from long-ago infections. And the scientific community is studying the reasons for the post-acute sequelae of SARS-CoV-2 (PASC). Until now, the studies provided varied reasons related to persistent COVID or PASC, such as acute SARS-CoV-2 injury in different organs, or reservoirs of the virus in certain tissues, as it happens with other pathogens like HIV. At the IDWeek 2022 infectious disease conference held this week in Washington, D.C., Eric Daar, chief of the Division of HIV Medicine at the Lundquist Institute at Harbor-UCLA Medical Center, moderated the session, 'COVID-19: Post-acute sequelae', where talks offered new results on the symptoms of people who have suffered prolonged COVID during the pandemic.
Read More
Respiratory

New DDR1/DDR2 inhibitors identified at Chiesi Farmaceutici

Oct. 19, 2022
No Comments
Chiesi Farmaceutici SpA has described new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
Read More
Lungs and bronchi
Respiratory

Hpvac-13 demonstrates protection against allergic asthma in animal model

Oct. 18, 2022
No Comments
Hpvac SA has announced new data on its lead compound Hpvac-13 for the treatment and prevention of asthmatic attacks in an animal disease model of allergic asthma.
Read More
Lungs
Inflammatory

Targeting calcium channels through ORAI1 deletion reduces allergic inflammation in the lung

Oct. 17, 2022
No Comments
T-cell activation and function depend on Ca2+ signals and Ca2+ influx after antigen binding to the T-cell receptor (TCR) is mediated by store-operated Ca2+ entry (SOCE) through Ca2+ release-activated Ca2+ (CRAC) channels in the plasma membrane.
Read More
Respiratory

Chiesi Farmaceutici discloses new DDR1 and DDR2 inhibitors

Oct. 14, 2022
No Comments
Chiesi Farmaceutici SpA has patented discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
Read More
Respiratory

Chiesi Farmaceutici presents new JAK inhibitors

Oct. 13, 2022
No Comments
Chiesi Farmaceutici SpA has identified tyrosine-protein kinase JAK1 and/or JAK2 and/or JAK3 and/or TYK2 inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and acute respiratory distress syndrome.
Read More
Respiratory

Humanwell Healthcare divulges new GPR84 inhibitors

Oct. 13, 2022
No Comments
Humanwell Healthcare (Group) Co. Ltd. has disclosed G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, autoimmune and metabolic diseases, among others.
Read More
Respiratory

Chiesi Farmaceutici identifies new JAK and TYK2 inhibitors

Oct. 11, 2022
No Comments
Chiesi Farmaceutici SpA has synthesized Janus kinase inhibitors, particularly JAK1, JAK2, JAK3 and nonreceptor tyrosine-protein kinase TYK2 inhibitors, reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and acute respiratory distress syndrome.
Read More
Respiratory

Idorsia Pharmaceuticals discloses new CFTR modulators

Oct. 10, 2022
No Comments
Idorsia Pharmaceuticals Ltd. has described cystic fibrosis transmembrane conductance regulator (CFTR) modulators reported to be useful for the treatment of cystic fibrosis.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 662 663 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 27, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for March 27, 2022.
  • Kirill Pevzner and Eran Seger - Protai

    AI drug discovery startup Protai raises $12M in seed funding

    BioWorld
    Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20...
  • Elderly woman holding illustration of brain with missing puzzle piece

    ‘Not a slowdown, a reversal’: Truebinding tackling Alzheimer’s via galectin-3

    BioWorld
    In Alzheimer’s, the amyloid beta hypothesis has proved most persistent in terms of drug development efforts to date, but aggregation of other pathogenic factors –...
  • Livzon licenses GERD drug from Onconic in $127.5M deal

    BioWorld
    Livzon Pharmaceutical Group Inc. licensed rights to zastaprazan, a gastroesophageal reflux disease (GERD) treatment candidate, from Onconic Therapeutics Inc. in a...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing